## Blue Cross Blue Shield/Blue Care Network of Michigan Medication Authorization Request Form



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For <u>commercial members only</u>, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION	PHYSICIAN INFORMATION	
Name	Name	
ID Number	Specialty	
D.O.B. /_/ MM/DD/YYYY	Address	
Diagnosis	City /State/Zip	
Drug Name Fulphila, Fylnetra, Neulasta, Neulasta Onpro, Nyvepria, Stimufend, Udenyca, Udenyca Onbody, Ziextenzo	Phone: Fax:	
Dose and Quantity	NPI	
Directions	Contact Person	
Date of Service(s)	Contact Person Phone / Ext.	
STEP 1: DISEASE STATE INFORMATION		
Required Demographic Information:  Patient Weight:kg		
Patient Height:ftinches		
Will the provider be administering the medication to the FEP member within the health plan's geographic service area?  \[ \begin{align*} \Pi \text{ Yes } \begin{align*} \Pi \text{ No, a prior authorization is not required through this process.} \end{align*}\]		
Prior authorizations are required for FEP members that will be serviced by a provider within the health plan's geographic service area. If you are not a provider in the geographic service area, please contact the health plan for questions regarding the FEP member's benefit requirements.		
<ul> <li>Is this member's FEP coverage primary or secondary coverage?</li> <li>☐ If primary, continue with question set.</li> <li>☐ If secondary, an authorization is not needed through this process. Please contact the member's primary coverage for determination of benefit and additional information.</li> </ul>		

<u>Crite</u> Please select i	ria Questions: nedication:	
□Fylnetra ( □ Neulasta (	pegfilgrastim-jmdb) pegfilgrastim-pbbk) (pegfilgrastim) Onpro (pegfilgrastim)	□ Nyvepria (pegfilgrastim-apgf) □ Stimufend (pegfilgrastim-fpgk) □ Udenyca (pegfilgrastim-cbqv) □ Udenyca Onbody (pegfilgrastim-cbqv) □ Ziextenzo (pegfilgrastim-bmez)
☐ Acute ra ☐ Prophyla ☐ Treatme	patient's diagnosis? diation syndrome axis for chemotherapy induced febrile neutropenia att of chemotherapy induced febrile neutropenia agnosis (please specify):	
(pegfilgrase excluding sextless (pegfilgrase) (pegfilgrase	stim-fpgk), or Ziextenzo (pegfilgrastim-bmez): Has the samples? □Yes □No*	npro (pegfilgrastim), Nyvepria (pegfilgrastim-apgf), Stimufend patient been on this medication continuously for the last 4 months r have they had an inadequate treatment response to ONE of the $\square$ Yes $\square$ No
-	ested medication being used in combination with another please specify the medication:	granulocyte colony-stimulating factor (G-CSF)? □Yes* □No
Chart notes are		er supporting medical information necessary for our review (required) ian's signature and date are not reflected on this document.
Request for exped	ited review: I certify that applying the standard review time frame may seriously jeopardize the	life or health of the member or the member's ability to regain maximum function
Physician's Nan Step 2: Checklist	Physician Signature  Form Completely Filled Out  Provide chart notes	Date  ☐ Attach test results
Step 3: Submit	By Fax: BCBSM Specialty Pharmacy Mailbox 1-877-325-5979	By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320